Overview

* Benitec fiscal Q1 net loss widens to $9 mln, with increased operating expenses

* Company raised $100 mln in oversubscribed public offering to fund BB-301 advancement

* BB-301 granted FDA Fast Track Designation after positive Phase 1b/2a trial results

Outlook

* Company plans to advance BB-301 development with FDA collaboration in 2026

* Benitec raised $100 mln to fund BB-301 OPMD program

Result Drivers

* CAPITAL RAISE - Co raised $100 mln in an oversubscribed public offering to fund BB-301 advancement and regulatory activities

* R&D: Company incurred $3.4 million of research and development expenses for the quarter

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 EPS -$0.22

Q1 Net -$9 mln

Income

Q1 -$8.90

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Benitec Biopharma Inc ( BNTC ) is $29.50, about 55.4% above its November 13 closing price of $13.15

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)